Compare SLN & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLN | USNA |
|---|---|---|
| Founded | 1994 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.4M | 371.5M |
| IPO Year | N/A | 1996 |
| Metric | SLN | USNA |
|---|---|---|
| Price | $5.01 | $21.38 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $39.67 | $36.00 |
| AVG Volume (30 Days) | ★ 355.5K | 115.9K |
| Earning Date | 02-26-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.90 |
| Revenue | $25,830,000.00 | ★ $912,670,000.00 |
| Revenue This Year | N/A | $10.42 |
| Revenue Next Year | N/A | $3.37 |
| P/E Ratio | ★ N/A | $24.63 |
| Revenue Growth | ★ 40.39 | 5.88 |
| 52 Week Low | $1.97 | $18.48 |
| 52 Week High | $7.78 | $38.32 |
| Indicator | SLN | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 54.57 |
| Support Level | $4.88 | $21.81 |
| Resistance Level | $6.13 | $22.59 |
| Average True Range (ATR) | 0.51 | 0.86 |
| MACD | -0.04 | 0.11 |
| Stochastic Oscillator | 10.40 | 58.81 |
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.